Abstract
Cancer therapies through ionizing radiation or chemotherapeutic treatment may result in DNA double strand breaks (DSBs) in cell. DNA-PK has emerged as an attractive target for drug discovery efforts toward DSBs repair and in V(D)J recombination. Hence, the search for potent and selective DNA-PK inhibitors has received particular attention and several series of activity inhibitors have been reported. In this article, we gave a report of the DNA-PK activation and the corresponding inhibitors, which belong to different chemical classes. Then homology modeling and molecular dynamics (MD) simulation were used to build the 3D model of DNA-PK receptor based on the X-ray structure of PI3K. All of the ligands were docked into the putative binding site of the 3D model of DNA-PK using the flexible docking method, and the probable interaction model between DNA-PK and the ligands were obtained. Based on the docking conformations and their alignment inside the binding pocket of DNA-PK, 3D QSAR analyses were performed on 259 ligands using CoMFA and CoMSIA methods. Both CoMFA and CoMSIA provide statistically valid models with good correlation and predictive power (CoMFA: q2 = 0.563, r2 =0.876; CoMSIA: q2 = 0.503, r2 =0.870). Our models would offer help to better comprehend the structure-activity relationship existent for this class of compounds and also facilitate the design of new inhibitors with good chemical derivsity.
Keywords: DNA-PK kinase, homology modeling, molecular dynamics, molecular docking, 3D-QSAR, CoMFA, CoMSIA
Current Pharmaceutical Design
Title: 3D-QSAR Studies on a Series of Inhibitors Docked into a New Homology Model of the DNA-PK Receptor
Volume: 15 Issue: 32
Author(s): Ran Cao, Huahui Zeng and Huabei Zhang
Affiliation:
Keywords: DNA-PK kinase, homology modeling, molecular dynamics, molecular docking, 3D-QSAR, CoMFA, CoMSIA
Abstract: Cancer therapies through ionizing radiation or chemotherapeutic treatment may result in DNA double strand breaks (DSBs) in cell. DNA-PK has emerged as an attractive target for drug discovery efforts toward DSBs repair and in V(D)J recombination. Hence, the search for potent and selective DNA-PK inhibitors has received particular attention and several series of activity inhibitors have been reported. In this article, we gave a report of the DNA-PK activation and the corresponding inhibitors, which belong to different chemical classes. Then homology modeling and molecular dynamics (MD) simulation were used to build the 3D model of DNA-PK receptor based on the X-ray structure of PI3K. All of the ligands were docked into the putative binding site of the 3D model of DNA-PK using the flexible docking method, and the probable interaction model between DNA-PK and the ligands were obtained. Based on the docking conformations and their alignment inside the binding pocket of DNA-PK, 3D QSAR analyses were performed on 259 ligands using CoMFA and CoMSIA methods. Both CoMFA and CoMSIA provide statistically valid models with good correlation and predictive power (CoMFA: q2 = 0.563, r2 =0.876; CoMSIA: q2 = 0.503, r2 =0.870). Our models would offer help to better comprehend the structure-activity relationship existent for this class of compounds and also facilitate the design of new inhibitors with good chemical derivsity.
Export Options
About this article
Cite this article as:
Cao Ran, Zeng Huahui and Zhang Huabei, 3D-QSAR Studies on a Series of Inhibitors Docked into a New Homology Model of the DNA-PK Receptor, Current Pharmaceutical Design 2009; 15 (32) . https://dx.doi.org/10.2174/138161209789649484
DOI https://dx.doi.org/10.2174/138161209789649484 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antithrombin, an Important Inhibitor in Blood Clots
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: GPCR-Targeted Drug Development)
Current Drug Targets Last Advances in Nanocarriers-Based Drug Delivery Systems for Colorectal Cancer
Current Drug Delivery Synthesis of Aza-BODIPY Boron Difluoride PDT Agents to Promote Apoptosis in HeLa Cells
Letters in Organic Chemistry Microwave Facilitated Green Synthesis and Characterization of Acrylamide Grafted Copolymer of Kheri (Acacia chundra) Gum Polysaccharide
The Natural Products Journal Microfluidic Assembly of Lipid Nanoparticles for Delivery of Antisense Oligonucleotides
Current Pharmaceutical Biotechnology Fermentation of Beet Juice Using Lactic Acid Bacteria and its Cytotoxic Activity Against Human Liver Cancer Cell Lines HepG2
Current Bioactive Compounds Genomic Instability and Carcinogenesis: An Update
Current Genomics Metal Complex-Peptide Conjugates: How to Modulate Bioactivity of Metal-Containing Compounds by the Attachment to Peptides
Current Medicinal Chemistry Regulation of Tumor-Stromal Fibroblast Interactions: Implications in Anticancer Therapy
Current Medicinal Chemistry Role of the Hsp90-Immunophilin Heterocomplex in Cancer Biology
Current Cancer Therapy Reviews Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives
Current Stem Cell Research & Therapy Interleukins Involved in Inflammatory Bowel Disease as New Therapeutic Targets
Current Immunology Reviews (Discontinued) Targeting the ERK Pathway: Novel Therapeutics for Thyroid Cancer
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Give Boron a Chance: Boron Containing Compounds Reach Ionotropic and Metabotropic Transmembrane Receptors
Mini-Reviews in Medicinal Chemistry MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting
Current Cancer Drug Targets Rapid Estrogen Signaling in Spermatogenesis
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells
Current Pharmaceutical Biotechnology Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery